Trade names Navoban Routes of
administration Oral, IV Molar mass 284.353 g/mol | Pregnancy
category AU: B3 ATC code A04AA03 (WHO) Protein binding 71% | |
 | ||
AHFS/Drugs.com International Drug Names Legal status AU: S4 (Prescription only)
UK: POM (Prescription only) | ||
Tropisetron (INN) is a serotonin 5-HT3 receptor antagonist used mainly as an antiemetic to treat nausea and vomiting following chemotherapy, although it has been used experimentally as an analgesic in cases of fibromyalgia. The drug is available in a 5 mg oral preparation or in 2 mg intravenous form. It is marketed by Novartis in Europe, Australia, New Zealand, Japan, South Korea and the Philippines as Navoban, but is not available in the U.S. It is also available from Novell Pharmaceutical Laboratories and marketed in several Asian countries as Setrovel.
Contents
Pharmacology
Tropisetron acts as both a selective 5-HT3 receptor antagonist and α7-nicotinic receptor agonist.
Adverse effects
Tropisetron is a well-tolerated drug with few side effects. Headache, constipation, and dizziness are the most commonly reported side effects associated with its use. Hypotension, transient liver enzyme elevation, immune hypersensitivity syndromes and extrapyramidal side effects have also been associated with its use on at least one occasion.There have been no significant drug interactions reported with this drug's use. It is broken down by the hepatic cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system.
Other uses
As a biological stain and as trypanocide.
